<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ALOSETRON HYDROCHLORIDE- alosetron hydrochloride tablet </strong><br>Roxane Laboratories, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use ALOSETRON Hydrochloride Tablets safely and effectively. See full prescribing information for ALOSETRON Hydrochloride Tablets. <br>ALOSETRON Hydrochloride Tablets Initial U.S. Approval: 2000</div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: SERIOUS GASTROINTESTINAL ADVERSE REACTIONS</h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning</span></span></h1>
<p class="Highlighta"><span class="Bold">Infrequent but serious gastrointestinal adverse reactions have been reported with the use of Alosetron Hydrochloride Tablets. These events, including <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span> and serious complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, have resulted in hospitalization and, rarely, blood transfusion, surgery, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span> </p>
<dl>
<dt>•</dt>
<dd><span class="Bold">Only prescribers who have enrolled in the Alosetron REMS Program should prescribe Alosetron Hydrochloride Tablets. (5.3) </span></dd>
<dt>•</dt>
<dd><span class="Bold">Alosetron Hydrochloride Tablets are indicated only for women with severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-predominant <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">irritable bowel syndrome</span> (IBS) who have not responded adequately to conventional therapy. (1) </span></dd>
<dt>•</dt>
<dd><span class="Bold">Discontinue Alosetron Hydrochloride Tablets immediately in patients who develop <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> or symptoms of <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>. Do not resume Alosetron Hydrochloride Tablets in patients who develop <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>. (2.1, 5.1, 5.2) </span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta">Contraindications, Lack of Understanding of Patient Acknowledgement Form (4.3) 09/2010 </p>
<p class="Highlighta">Warnings and Precautions, Alosetron REMS Program (5.3) 09/2010  </p>
<p class="Highlighta">Patient Counseling Information (17) 09/2010 </p>
</div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: SERIOUS GASTROINTESTINAL ADVERSE REACTIONS</h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning</span></span></h1>
<p class="Highlighta"><span class="Bold">Infrequent but serious gastrointestinal adverse reactions have been reported with the use of Alosetron Hydrochloride Tablets. These events, including <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span> and serious complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, have resulted in hospitalization and, rarely, blood transfusion, surgery, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span> </p>
<dl>
<dt>•</dt>
<dd><span class="Bold">Only prescribers who have enrolled in the Alosetron REMS Program should prescribe Alosetron Hydrochloride Tablets. (5.3) </span></dd>
<dt>•</dt>
<dd><span class="Bold">Alosetron Hydrochloride Tablets are indicated only for women with severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-predominant <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">irritable bowel syndrome</span> (IBS) who have not responded adequately to conventional therapy. (1) </span></dd>
<dt>•</dt>
<dd><span class="Bold">Discontinue Alosetron Hydrochloride Tablets immediately in patients who develop <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> or symptoms of <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>. Do not resume Alosetron Hydrochloride Tablets in patients who develop <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>. (2.1, 5.1, 5.2) </span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Alosetron Hydrochloride Tablets are a selective serotonin 5-HT<span class="Sub">3</span> antagonist indicated only for women with severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-predominant <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">irritable bowel syndrome</span> (IBS) who have:   (<a href="#section-1">1</a>)</p>
<dl>
<dt>•</dt>
<dd>chronic IBS symptoms (generally lasting 6 months or longer), </dd>
<dt>•</dt>
<dd>had anatomic or biochemical abnormalities of the gastrointestinal tract excluded, and </dd>
<dt>•</dt>
<dd>not responded adequately to conventional therapy.</dd>
</dl>
<p class="Highlighta">Severe IBS includes <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and 1 or more of the following:  (<a href="#section-1">1</a>)</p>
<dl>
<dt>•</dt>
<dd>frequent and severe <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>/<span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, </dd>
<dt>•</dt>
<dd>frequent bowel urgency or <span class="product-label-link" type="condition" conceptid="197675" conceptname="Incontinence of feces">fecal incontinence</span>, </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> or restriction of daily activities due to IBS.</dd>
</dl>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>•</dt>
<dd>Starting dose is 0.5 mg twice a day (2.1) </dd>
<dt>•</dt>
<dd>May increase dose to 1 mg twice a day after 4 weeks if starting dosage is well tolerated but does not adequately control IBS symptoms (2.1) </dd>
<dt>•</dt>
<dd>Discontinue Alosetron Hydrochloride Tablets in patients who have not had adequate control of IBS symptoms after 4 weeks of treatment with 1 mg twice a day. (2.1) </dd>
</dl></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets: 0.5 and 1 mg  (<a href="#section-3">3</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Do not initiate in patients with <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (4.1)</dd>
<dt>•</dt>
<dd>History of chronic or severe <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> or sequelae from <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>; <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, stricture, toxic <span class="product-label-link" type="condition" conceptid="198465" conceptname="Megacolon, not Hirschsprung's">megacolon</span>, <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">gastrointestinal perforation</span>, and/or <span class="product-label-link" type="condition" conceptid="4175338" conceptname="Adhesion">adhesions</span>; <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>; impaired intestinal circulation, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, or hypercoagulable state; Crohn’s disease or <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>; <span class="product-label-link" type="condition" conceptid="4109737" conceptname="Diverticulitis">diverticulitis</span>; severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (4.2) </dd>
<dt>•</dt>
<dd>Inability to understand or comply with the Patient Acknowledgement Form (4.3) </dd>
<dt>•</dt>
<dd>Concomitant use of fluvoxamine (4.4) </dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Serious Complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>: May occur in some patients without warning. Include obstruction, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>, impaction, toxic <span class="product-label-link" type="condition" conceptid="198465" conceptname="Megacolon, not Hirschsprung's">megacolon</span>, and secondary <span class="product-label-link" type="condition" conceptid="192673" conceptname="Vascular insufficiency of intestine">bowel ischemia</span> and in rare cases perforation and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported. Risk is increased in patients who are elderly, debilitated, or taking medications that decrease bowel motility. (5.1) </dd>
<dt>•</dt>
<dd>Discontinue Alosetron Hydrochloride Tablets immediately if <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> occurs. (5.1) </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">Ischemic colitis</span>: May occur in some patients without warning. Promptly evaluate patients with signs of <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span> (e.g., <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal bleeding</span>, <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span>, new or worsening <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>). (5.2) </dd>
<dt>•</dt>
<dd>Discontinue Alosetron Hydrochloride Tablets immediately if signs of <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span> occur, such as <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal bleeding</span>, <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span>, or new or worsening <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>. (5.2) </dd>
<dt>•</dt>
<dd>To prescribe Alosetron Hydrochloride Tablets, prescribers must be enrolled in the Alosetron REMS Program and adhere to all components of the Program. (5.3) </dd>
</dl></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (incidence &gt;2% and &gt;placebo) in clinical studies were <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span> and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">gastrointestinal discomfort</span> and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. (6.1)  </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Roxane Laboratories, Inc. at 1-800-962-8364 or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a></span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>CYP1A2 inhibitors: Avoid concomitant uses because of increased exposure and half-life of alosetron. Use with fluvoxamine is contraindicated. (4.3, 7.1) </dd>
<dt>•</dt>
<dd>CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (7.2) </dd>
</dl></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic impairment</span>: Contraindicated in severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Use with caution in patients with mild or moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. (4.2, 8.6) </dd>
<dt>•</dt>
<dd>Geriatric use: Elderly patients may be at greater risk for complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>.</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 5/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: SERIOUS GASTROINTESTINAL ADVERSE REACTIONS</a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Adult Patients</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Patients With Hepatic Impairment  </a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Information for Pharmacists</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1 Constipation  </a></h2>
<h2><a href="#section-4.2" class="toc">4.2 History of Severe Bowel or Hepatic Disorders </a></h2>
<h2><a href="#section-4.3" class="toc"><span class="XmChange">4.3 Lack of Understanding of Patient Acknowledgement Form</span></a></h2>
<h2><a href="#section-4.4" class="toc">4.4 Concomitant Use of Fluvoxamine  </a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Serious Complications of Constipation  </a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">Ischemic Colitis</span></a></h2>
<h2><a href="#section-5.3" class="toc"><span class="XmChange">5.3 Alosetron REMS Program </span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience  </a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience  </a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 CYP1A2 Inhibitors  </a></h2>
<h2><a href="#section-7.2" class="toc">7.2 CYP3A4 Inhibitors  </a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Other CYP Enzymes  </a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 Renal Impairment   </a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Dose-Ranging Study  </a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Efficacy Studies  </a></h2>
<h2><a href="#section-13.3" class="toc">14.3 Long-Term Use  </a></h2>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="id_2566e98c-cc83-4233-be60-e7389a8358b4"></a><a name="section-1"></a><p></p>
<h1>WARNING: SERIOUS GASTROINTESTINAL ADVERSE REACTIONS</h1>
<p class="First"><span class="Bold">Infrequent but serious gastrointestinal adverse reactions have been reported with the use of Alosetron Hydrochloride Tablets. These events, including <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span> and serious complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, have resulted in hospitalization, and rarely, blood transfusion, surgery, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. </span></p>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">The Alosetron REMS Program was implemented to help reduce risks of serious gastrointestinal adverse reactions. Only prescribers who have enrolled in the Alosetron REMS Program, based on their understanding of the benefits and risks, should prescribe Alosetron Hydrochloride Tablets </span><span class="Bold"><span class="Italics"><span class="Underline"><a href="#i4i_warnings_precautions_id_996a356d-2a00-4884-8e4e-2a033317576b">[see Warnings and Precautions (5.3)]</a></span></span></span><span class="Bold">. </span>
</dd>
<dt>•</dt>
<dd><span class="Bold">Alosetron Hydrochloride Tablets are indicated only for women with severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-predominant <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">irritable bowel syndrome</span> (IBS) who have not responded adequately to conventional therapy <span class="Italics"><span class="Underline"><a href="#i4i_indications_id_95bdf1f4-a93f-44fa-ac01-03a319cf603f">[see Indications and Usage (1)]</a></span></span>. Before receiving the initial prescription for Alosetron Hydrochloride Tablets, the patient must read and sign the Patient Acknowledgement Form for Alosetron Hydrochloride Tablets <span class="Italics"><span class="Underline"><a href="#i4i_info_patients_id_b6032ac2-f750-4e1a-a60c-176aef7bde8a">[see Patient Counseling Information (17)]</a></span></span>. </span></dd>
<dt>•</dt>
<dd><span class="Bold">Alosetron Hydrochloride Tablets should be discontinued immediately in patients who develop <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> or symptoms of <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>. Patients should immediately report <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> or symptoms of <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span> to their prescriber. Alosetron Hydrochloride Tablets should not be resumed in patients who develop <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>. Patients who have <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> should immediately contact their prescriber if the <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> does not resolve after Alosetron Hydrochloride Tablets is discontinued. Patients with resolved <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> should resume Alosetron Hydrochloride Tablets only on the advice of their treating prescriber <span class="Italics"><span class="Underline"><a href="#i4i_dosage_admin_id_b7d9679f-72a2-4695-a729-46cd045c164f">[see Dosage and Administration (2.1), Warnings and Precautions (5.1), (5.2)]</a></span></span>. </span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_95bdf1f4-a93f-44fa-ac01-03a319cf603f"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Alosetron Hydrochloride Tablets are indicated only for women with severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-predominant <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">irritable bowel syndrome</span> (IBS) who have: </p>
<dl>
<dt>•</dt>
<dd>chronic IBS symptoms (generally lasting 6 months or longer), </dd>
<dt>•</dt>
<dd>had anatomic or biochemical abnormalities of the gastrointestinal tract excluded, and </dd>
<dt>•</dt>
<dd>not responded adequately to conventional therapy. </dd>
</dl>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>-predominant IBS is severe if it includes <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and one or more of the following:</p>
<dl>
<dt>•</dt>
<dd>frequent and severe <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>/<span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, </dd>
<dt>•</dt>
<dd>frequent bowel urgency or <span class="product-label-link" type="condition" conceptid="197675" conceptname="Incontinence of feces">fecal incontinence</span>, </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> or restriction of daily activities due to IBS. </dd>
</dl>
<p>Because of infrequent but serious gastrointestinal adverse reactions associated with Alosetron Hydrochloride Tablets, the indication is restricted to those patients for whom the benefit-to-risk balance is most favorable. </p>
<p>Clinical studies have not been performed to adequately confirm the benefits of Alosetron Hydrochloride Tablets in men. </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_b7d9679f-72a2-4695-a729-46cd045c164f"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">For safety reasons, only physicians who enroll in the Alosetron REMS Program should prescribe Alosetron Hydrochloride Tablets <span class="Italics"><span class="Underline"><a href="#i4i_warnings_precautions_id_996a356d-2a00-4884-8e4e-2a033317576b">[see Warnings and Precautions (5.3)]</a></span></span><span class="Italics">.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_64625fb1-94d1-4994-9b79-74e7240f16fa"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Adult Patients</h2>
<p class="First">To lower the risk of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, Alosetron Hydrochloride Tablets should be started at a dosage of 0.5 mg twice a day. Patients who become constipated at this dosage should stop taking Alosetron Hydrochloride Tablets until the <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> resolves. They may be restarted at 0.5 mg once a day. If <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> recurs at the lower dose, Alosetron Hydrochloride Tablets should be discontinued immediately. </p>
<p>Patients well controlled on 0.5 mg once or twice a day may be maintained on this regimen. If after 4 weeks the dosage is well tolerated but does not adequately control IBS symptoms, then the dosage can be increased to up to 1 mg twice a day<span class="Bold">. Alosetron Hydrochloride Tablets should be discontinued in patients who have not had adequate control of IBS symptoms after 4 weeks of treatment with 1 mg twice a day. </span></p>
<p>Alosetron Hydrochloride Tablets can be taken with or without food <span class="Italics"><span class="Underline"><a href="#i4i_clinical_pharmacology_id_7bdbd3a8-7734-4ec8-88cf-ab065d0e7343">[see Clinical Pharmacology (12.3)]</a></span></span>. </p>
<p>Alosetron Hydrochloride Tablets should be discontinued immediately in patients who develop <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> or signs of <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>. Alosetron Hydrochloride Tablets should not be restarted in patients who develop <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>. </p>
<p>Clinical trial and postmarketing experience suggest that debilitated patients or patients taking additional medications that decrease gastrointestinal motility may be at greater risk of serious complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. Therefore, appropriate caution and follow-up should be exercised if Alosetron Hydrochloride Tablets are prescribed for these patients. </p>
<p>Postmarketing experience suggests that elderly patients may be at greater risk for complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>; therefore, appropriate caution and follow-up should be exercised if Alosetron Hydrochloride Tablets are prescribed for these patients <span class="Italics"><span class="Underline"><a href="#i4i_warnings_precautions_id_996a356d-2a00-4884-8e4e-2a033317576b">[see Warnings and Precautions (5.1)]</a></span></span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b577a896-864d-4acf-9c77-6b73c401a031"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Patients With Hepatic Impairment  </h2>
<p class="First">Alosetron Hydrochloride Tablets is extensively metabolized by the liver, and increased exposure to Alosetron Hydrochloride Tablets is likely to occur in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Increased drug exposure may increase the risk of serious adverse reactions. Alosetron Hydrochloride Tablets should be used with caution in patients with mild or moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and is contraindicated in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics"><span class="Underline"><a href="#i4i_contraindications_id_4712fa45-2dfa-4135-a5bf-821afe504712">[see CONTRAINDICATIONS (4)]</a></span></span><span class="Italics"><span class="Underline"> and</span></span><span class="Italics"><span class="Underline"><a href="#i4i_specific_populations_id_8bf670bc-dc9d-446f-bb7b-62c3ad665e7b"> USE IN SPECIFIC POPULATIONS (8.6)]</a></span></span><span class="Italics">. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_329308da-d73c-4199-8114-30425deef9ac"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Information for Pharmacists</h2>
<p class="First">Alosetron Hydrochloride Tablets may be dispensed only on presentation of a prescription for Alosetron Hydrochloride Tablets with a sticker for the Alosetron REMS Program attached. A Medication Guide for Alosetron Hydrochloride Tablets must be given to the patient each time Alosetron Hydrochloride Tablets are dispensed as required by law. No telephone, facsimile, or computerized prescriptions are permitted with this program. Refills are permitted to be written on prescriptions<span class="Italics">. </span></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_e8600e20-2aad-4776-b54d-65c981fff83b"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">0.5 mg and 1 mg tablets </p>
<p>Alosetron Hydrochloride Tablets, 0.5 mg (0.562 mg alosetron HCl equivalent to 0.5 mg alosetron), are white to off-white, round biconvex tablets, debossed with 54 628 on one side and plain on the other side. </p>
<p>Alosetron Hydrochloride Tablets, 1 mg (1.124 mg alosetron HCl equivalent to 1 mg alosetron), are white to off-white, round biconvex tablets, debossed with 54 974 on one side and plain on the other side. </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_4712fa45-2dfa-4135-a5bf-821afe504712"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9f9592f9-f03c-44c1-94cd-f1271334d4b9"></a><a name="section-4.1"></a><p></p>
<h2>4.1 Constipation  </h2>
<p class="First">Alosetron Hydrochloride Tablets <span class="Bold">should not be initiated </span>in patients with <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> <span class="Italics"><span class="Underline"><a href="#i4i_warnings_precautions_id_996a356d-2a00-4884-8e4e-2a033317576b">[see Warnings and Precautions (5.1)]</a></span></span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_79964e16-ae67-4a69-b97b-596cf01e6727"></a><a name="section-4.2"></a><p></p>
<h2>4.2 History of Severe Bowel or Hepatic Disorders </h2>
<p class="First">Alosetron Hydrochloride Tablets are contraindicated in patients with a history of the following: </p>
<dl>
<dt>•</dt>
<dd>chronic or severe <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> or sequelae from <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, stricture, toxic <span class="product-label-link" type="condition" conceptid="198465" conceptname="Megacolon, not Hirschsprung's">megacolon</span>, <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">gastrointestinal perforation</span>, and/or <span class="product-label-link" type="condition" conceptid="4175338" conceptname="Adhesion">adhesions</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>, impaired intestinal circulation, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, or hypercoagulable state </dd>
<dt>•</dt>
<dd>Crohn’s disease or <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4109737" conceptname="Diverticulitis">diverticulitis</span> </dd>
<dt>•</dt>
<dd>severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> </dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_577aa8c8-587b-4d30-9c32-2fbd8a4b018e"></a><a name="section-4.3"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">4.3 Lack of Understanding of Patient Acknowledgement Form</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Alosetron Hydrochloride Tablets should not be used by patients who are unable to understand or comply with the Patient Acknowledgement Form for Alosetron Hydrochloride Tablets </span><span class="Italics"><span class="Underline"><a href="#i4i_info_patients_id_b6032ac2-f750-4e1a-a60c-176aef7bde8a">[see Patient Counseling Information (17)]</a></span></span><span class="XmChange">. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_36f2aefa-85e8-413a-a81f-8e1540baa955"></a><a name="section-4.4"></a><p></p>
<h2>4.4 Concomitant Use of Fluvoxamine  </h2>
<p class="First">Concomitant administration of Alosetron Hydrochloride Tablets with fluvoxamine are contraindicated. Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold <span class="Italics"><span class="Underline"><a href="#i4i_interactions_id_0cef209a-da3e-430d-b9cf-e13037e577a5">[see Drug Interactions (7.1)]</a></span></span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_996a356d-2a00-4884-8e4e-2a033317576b"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_616df8e8-2e53-47b5-89fd-b64eee40b596"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Serious Complications of Constipation  </h2>
<p class="First"><span class="Bold">Some patients have experienced serious complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> without warning</span>. </p>
<p>Serious complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, including obstruction, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>, impaction, toxic <span class="product-label-link" type="condition" conceptid="198465" conceptname="Megacolon, not Hirschsprung's">megacolon</span>, and secondary <span class="product-label-link" type="condition" conceptid="192673" conceptname="Vascular insufficiency of intestine">bowel ischemia</span>, have been reported with use of Alosetron Hydrochloride Tablets during clinical trials. Complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> have been reported with use of 1 mg twice daily and with lower doses. A dose response relationship has not been established for serious complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. <span class="Bold">The incidence of serious complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> was approximately 0.1% (1 per 1,000 patients) in women receiving either Alosetron Hydrochloride Tablets or placebo. </span>In addition, rare cases of perforation and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported from postmarketing clinical practice. In some cases, complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> required intestinal surgery, including colectomy. Patients who are elderly, debilitated, or taking additional medications that decrease gastrointestinal motility may be at greater risk for complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. </p>
<p>Alosetron Hydrochloride Tablets should be discontinued immediately in patients who develop <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> <span class="Italics">[see Boxed Warning]. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_61232500-96bd-45bf-a422-4d1da82a229f"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">Ischemic Colitis</span></h2>
<p class="First"><span class="Bold">Some patients have experienced <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span> without warning. </span></p>
<p><span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">Ischemic colitis</span> has been reported in patients receiving Alosetron Hydrochloride Tablets in clinical trials as well as during marketed use of the drug. <span class="Bold">In IBS clinical trials, the cumulative incidence of <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span> in women receiving Alosetron Hydrochloride Tablets was 0.2% (2 per 1,000 patients, 95% confidence interval 1 to 3) through 3 months and was 0.3% (3 per 1,000 patients, 95% confidence interval 1 to 4) through 6 months. </span><span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">Ischemic colitis</span> has been reported with use of 1 mg twice daily and with lower doses. A dose-response relationship has not been established. <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">Ischemic colitis</span> was reported in one patient receiving placebo. The patient experience in controlled clinical trials is insufficient to estimate the incidence of <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span> in patients taking Alosetron Hydrochloride Tablets for longer than 6 months<span class="Bold">. </span></p>
<p>Alosetron Hydrochloride Tablets should be discontinued immediately in patients with signs of <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span> such as <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal bleeding</span>, <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span>, or new or worsening <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>. Because <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span> can be life-threatening, patients with signs or symptoms of <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span> should be evaluated promptly and have appropriate diagnostic testing performed. Treatment with Alosetron Hydrochloride Tablets should not be resumed in patients who develop <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_62cbfdd1-7638-4dcf-9815-9766ca3942c8"></a><a name="section-5.3"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">5.3 Alosetron REMS Program </span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">To prescribe Alosetron Hydrochloride Tablets, the prescriber must be enrolled in the Alosetron REMS Program. To enroll, prescribers must understand the benefits and risks of treatment with Alosetron Hydrochloride Tablets for severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-predominant IBS, including the information in the Prescribing Information, Medication Guide, and Patient Acknowledgement Form for Alosetron Hydrochloride Tablets.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">To enroll in the Alosetron REMS Program, call 1-844-267-8675 or visit www.AlosetronREMS.com to complete the Prescriber Enrollment Form.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_39fa62b5-ff6a-4afa-99c3-62e953b5c30b"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are described in more detail in other sections of the label: </p>
<dl>
<dt>•</dt>
<dd>Complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> <span class="Italics">[see Boxed Warning, </span><span class="Italics"><span class="Underline"><a href="#i4i_warnings_precautions_id_996a356d-2a00-4884-8e4e-2a033317576b">Warnings and Precautions (5.1)]</a></span></span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">Ischemic colitis</span> <span class="Italics">[see Boxed Warning, </span><span class="Italics"><span class="Underline"><a href="#i4i_warnings_precautions_id_996a356d-2a00-4884-8e4e-2a033317576b">Warnings and Precautions (5.2)]</a></span></span>
</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_33695c68-66d2-4270-bc32-f9f0c5e6a41b"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience  </h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. </p>
<p><span class="Underline">Patients With <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">Irritable Bowel Syndrome</span>: </span>Table 1 summarizes adverse reactions from 22 repeat-dose studies in patients with IBS who were treated with 1 mg of alosetron hydrochloride tablets twice daily for 8 to 24 weeks. The adverse reactions in Table 1 were reported in 1% or more of patients who received alosetron hydrochloride tablets and occurred more frequently on alosetron hydrochloride tablets than on placebo. A statistically significant difference was observed for <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> in patients treated with alosetron hydrochloride tablets compared to placebo (p&lt;0.0001). </p>
<a name="_Refid_55b55f46-930f-4f30-bc1c-46a169723"></a><table width="100%">
<caption><span>Table 1: Adverse Reactions Reported in ≥1% of Patients With <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">Irritable Bowel Syndrome</span> and More Frequently on Alosetron Hydrochloride Tablets 1 mg Twice Daily Than Placebo</span></caption>
<col width="54%">
<col width="19%">
<col width="27%">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule"></td>
<td class="Lrule Rrule Toprule"></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First">Alosetron Hydrochloride Tablets</p></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center"><p class="First">Body System </p></td>
<td class="Lrule Rrule" align="center"><p class="First">Placebo </p></td>
<td class="Lrule Rrule" align="center"><p class="First">1 mg twice daily </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">Adverse Reaction </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(n = 2,363) </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(n = 8,328) </p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="First">Gastrointestinal </p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">6% </p></td>
<td class="Botrule Rrule" align="center"><p class="First">29% </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">Abdominal discomfort</span> and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">4% </p></td>
<td class="Botrule Rrule" align="center"><p class="First">7% </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">5% </p></td>
<td class="Botrule Rrule" align="center"><p class="First">6% </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">Gastrointestinal discomfort</span> and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">3% </p></td>
<td class="Botrule Rrule" align="center"><p class="First">5% </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">1% </p></td>
<td class="Botrule Rrule" align="center"><p class="First">2% </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4301596" conceptname="Regurgitation">Regurgitation</span> and reflux </p></td>
<td class="Botrule Rrule" align="center"><p class="First">2% </p></td>
<td class="Botrule Rrule" align="center"><p class="First">2% </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="194382" conceptname="External hemorrhoids">Hemorrhoids</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">1% </p></td>
<td class="Botrule Rrule" align="center"><p class="First">2% </p></td>
</tr>
</tbody>
</table>
<p><span class="Italics">Gastrointestinal: </span><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> is a frequent and dose-related side effect of treatment with alosetron hydrochloride tablets <span class="Italics"><span class="Underline"><a href="#i4i_warnings_precautions_id_996a356d-2a00-4884-8e4e-2a033317576b">[see Warnings and Precautions (5.1)]</a></span></span>. In clinical studies <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> was reported in approximately 29% of patients with IBS treated with alosetron hydrochloride tablets 1 mg twice daily (n = 9,316). This effect was statistically significant compared to placebo (p&lt;0.0001). Eleven percent (11%) of patients treated with alosetron hydrochloride tablets 1 mg twice daily withdrew from the studies due to <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. Although the number of patients with IBS treated with alosetron hydrochloride tablets 0.5 mg twice daily is relatively small (n = 243), only 11% of those patients reported <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> and 4% withdrew from clinical studies due to <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. Among the patients treated with alosetron hydrochloride tablets 1 mg twice daily who reported <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, 75% reported a single episode and most reports of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (70%) occurred during the first month of treatment, with the median time to first report of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> onset of 8 days. Occurrences of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> in clinical trials were generally mild to moderate in intensity, transient in nature, and resolved either spontaneously with continued treatment or with an interruption of treatment. However, serious complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> have been reported in clinical studies and in postmarketing experience <span class="Italics"><span class="Underline"><a href="#i4i_warnings_precautions_id_996a356d-2a00-4884-8e4e-2a033317576b">[see Boxed Warning and Warnings and Precautions (5.1)]</a></span></span>. In Studies 1 and 2, 9% of patients treated with alosetron hydrochloride tablets reported <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> and 4 consecutive days with no bowel movement <span class="Italics"><span class="Underline"><a href="#i4i_clinical_studies_id_12145a9e-f155-4a04-8bd8-6f92beb1706b">[see Clinical Studies (14.2)]</a></span></span>. Following interruption of treatment, 78% of the affected patients resumed bowel movements within a 2-day period and were able to re-initiate treatment with alosetron hydrochloride tablets. </p>
<p><span class="Italics">Hepatic: </span>A similar incidence in elevation of ALT (&gt;2-fold) was seen in patients receiving alosetron hydrochloride tablets or placebo (1% vs. 1.2%). A single case of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> (elevated ALT, AST, alkaline phosphatase, and bilirubin) without <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> in a patient receiving alosetron hydrochloride tablets was reported in a 12-week study. A causal association with alosetron hydrochloride tablets has not been established. </p>
<p><span class="Italics">Long-Term Safety: </span>Patient experience in controlled clinical trials is insufficient to estimate the incidence of <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span> in patients taking alosetron hydrochloride tablets for longer than 6 months. </p>
<p><span class="Underline">Women With Severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>-Predominant <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">Irritable Bowel Syndrome</span>: </span>Table 2 summarizes the gastrointestinal adverse reactions from 1 repeat-dose study in female patients with severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-predominant IBS who were treated for 12 weeks. The adverse reactions in Table 2 were reported in 3% or more of patients who received alosetron hydrochloride tablets and occurred more frequently with alosetron hydrochloride tablets than with placebo. Other events reported in 3% or more of patients who received alosetron hydrochloride tablets and occurring more frequently with alosetron hydrochloride tablets than with placebo included <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="201218" conceptname="Epidemic vomiting syndrome">viral gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>. </p>
<a name="_Refid_c9308b99-7e06-4a26-b31d-8418595dc"></a><table width="100%">
<caption><span>Table 2: Gastrointestinal Adverse Reactions Reported in ≥3% of Women With Severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>-Predominant <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">Irritable Bowel Syndrome</span> and More Frequently on Alosetron Hydrochloride Tablets Than Placebo.</span></caption>
<col width="20%">
<col width="20%">
<col width="20%">
<col width="19%">
<col width="19%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="3"><p class="First">Adverse Reaction </p></td>
<td class="Lrule Rrule Toprule" align="center" rowspan="2"><p class="First">Placebo </p></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First">Alosetron HCl</p></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First">Alosetron HCl</p></td>
<td class="Lrule Toprule" align="center"><p class="First">Alosetron HCl</p></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center"><p class="First">0.5 mg once daily </p></td>
<td class="Lrule Rrule" align="center"><p class="First">1 mg once daily </p></td>
<td class="Lrule" align="center"><p class="First">1 mg twice daily </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(n = 176)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(n = 175) </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(n = 172)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(n = 176)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> </p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">5% </p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">9% </p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">16% </p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">19% </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">3% </p></td>
<td class="Botrule Rrule" align="center"><p class="First">5% </p></td>
<td class="Botrule Rrule" align="center"><p class="First">6% </p></td>
<td class="Botrule Rrule" align="center"><p class="First">7% </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">2% </p></td>
<td class="Botrule Rrule" align="center"><p class="First">3% </p></td>
<td class="Botrule Rrule" align="center"><p class="First">2% </p></td>
<td class="Botrule Rrule" align="center"><p class="First">2% </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">
<p class="First">Hemorrhoidal </p>
<p><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> </p>
</td>
<td class="Botrule Rrule" align="center"><p class="First">2% </p></td>
<td class="Botrule Rrule" align="center"><p class="First">3% </p></td>
<td class="Botrule Rrule" align="center"><p class="First">2% </p></td>
<td class="Botrule Rrule" align="center"><p class="First">2% </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">2% </p></td>
<td class="Botrule Rrule" align="center"><p class="First">2% </p></td>
<td class="Botrule Rrule" align="center"><p class="First">1% </p></td>
<td class="Botrule Rrule" align="center"><p class="First">3% </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="194382" conceptname="External hemorrhoids">Hemorrhoids</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">2% </p></td>
<td class="Botrule Rrule" align="center"><p class="First">1% </p></td>
<td class="Botrule Rrule" align="center"><p class="First">1% </p></td>
<td class="Botrule Rrule" align="center"><p class="First">3% </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule">
<p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> </p>
<p>upper </p>
</td>
<td class="Botrule Rrule" align="center"><p class="First">1% </p></td>
<td class="Botrule Rrule" align="center"><p class="First">3% </p></td>
<td class="Botrule Rrule" align="center"><p class="First">1% </p></td>
<td class="Botrule Rrule" align="center"><p class="First">1% </p></td>
</tr>
</tbody>
</table>
<p>Adverse reactions reported in another study of 701 women with severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-predominant IBS were similar to those shown in Table 2. Gastrointestinal adverse reactions reported in 3% or more of patients who received alosetron hydrochloride tablets and occurring more frequently with alosetron hydrochloride tablets than with placebo included <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (14% and 10% of patients taking alosetron hydrochloride tablets 1 mg twice daily or 0.5 mg as needed, respectively, compared with 2% taking placebo), <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>. Other events reported in 3% or more of patients who received alosetron hydrochloride tablets and occurring more frequently with alosetron hydrochloride tablets than with placebo included <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="201218" conceptname="Epidemic vomiting syndrome">viral gastroenteritis</span>, and <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>. </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>: </span><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> was the most frequent adverse reaction among women with severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-predominant IBS represented in Table 2. There was a dose response in the groups treated with alosetron hydrochloride tablets in the number of patients withdrawn due to <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (2% on placebo, 5% on 0.5 mg once daily, 8% on 1 mg once daily, and 11% on 1 mg twice daily). Among these patients with severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-predominant IBS treated with alosetron hydrochloride tablets who reported <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> most (75%) reported one episode which occurred within the first 15 days of treatment and persisted for 4 to 5 days. </p>
<p><span class="Underline">Other Events Observed During Clinical Evaluation of Alosetron Hydrochloride Tablets: </span>During its assessment in clinical trials, multiple and single doses of alosetron hydrochloride tablets were administered, resulting in 11,874 subject exposures in 86 completed clinical studies. The conditions, dosages, and duration of exposure to alosetron hydrochloride tablets varied between trials, and the studies included healthy male and female volunteers as well as male and female patients with IBS and other indications. </p>
<p>In the listing that follows, reported adverse reactions were classified using a standardized coding dictionary. Only those events that an investigator believed were possibly related to alosetron hydrochloride tablets, occurred in at least 2 patients, and occurred at a greater frequency during treatment with alosetron hydrochloride tablets than during placebo administration are presented. Serious adverse reactions occurring in at least 1 patient for whom an investigator believed there was reasonable possibility that the event was related to treatment with alosetron hydrochloride tablets and occurring at a greater frequency in patients treated with alosetron hydrochloride tablets than placebo-treated patients are also presented. </p>
<p>In the following listing, events are categorized by body system. Within each body system, events are presented in descending order of frequency. The following definitions are used: <span class="Italics">infrequent </span>adverse reactions are those occurring on one or more occasion in 1/100 to 1/1,000 patients; <span class="Italics">rare </span>adverse reactions are those occurring on one or more occasion in fewer than 1/1,000 patients. </p>
<p>Although the events reported occurred during treatment with alosetron hydrochloride tablets, they were not necessarily caused by it. </p>
<p><span class="Italics">Blood and Lymphatic: Rare: </span>Quantitative red cell or hemoglobin defects, and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>. </p>
<p><span class="Italics">Cardiovascular: Infrequent: </span><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachyarrhythmias</span>. <span class="Italics">Rare: </span><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">increased blood pressure</span>, and <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">extrasystoles</span>. </p>
<p><span class="Italics">Drug Interaction, <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span>, and <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">Trauma</span>: Rare: </span><span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">Contusions</span> and <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span>. </p>
<p><span class="Italics">Ear, Nose, and Throat: Rare: </span>Ear, nose, and <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">throat infections</span>; viral ear, nose, and <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">throat infections</span>; and <span class="product-label-link" type="condition" conceptid="24969" conceptname="Laryngitis">laryngitis</span>. </p>
<p><span class="Italics">Endocrine and Metabolic: Rare: </span>Disorders of calcium and phosphate metabolism, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, hypothalamus/pituitary hypofunction, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, and fluid disturbances. </p>
<p><span class="Italics">Eye: Rare: </span>Light sensitivity of eyes. </p>
<p><span class="Italics">Gastrointestinal: Infrequent: </span>Hyposalivation, dyspeptic symptoms, gastrointestinal <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span>, <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span> <span class="Italics">[see Warnings and Precautions (5.2)]</span>, and gastrointestinal lesions. <span class="Italics">Rare: </span>Abnormal <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, gastrointestinal signs and symptoms, <span class="product-label-link" type="condition" conceptid="4215578" conceptname="Proctitis">proctitis</span>, <span class="product-label-link" type="condition" conceptid="4109737" conceptname="Diverticulitis">diverticulitis</span>, positive fecal occult blood, <span class="product-label-link" type="condition" conceptid="4265627" conceptname="Hyperchlorhydria">hyperacidity</span>, decreased gastrointestinal motility and <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>, <span class="product-label-link" type="condition" conceptid="4129389" conceptname="Gastrointestinal obstruction">gastrointestinal obstructions</span>, oral symptoms, gastrointestinal <span class="product-label-link" type="condition" conceptid="4149485" conceptname="Intussusception">intussusception</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="195306" conceptname="Gastroduodenitis">gastroduodenitis</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, and <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>. </p>
<p><span class="Italics">Hepatobiliary Tract and Pancreas: Rare: </span>Abnormal bilirubin levels and <span class="product-label-link" type="condition" conceptid="192956" conceptname="Cholecystitis">cholecystitis</span>. </p>
<p><span class="Italics">Lower Respiratory: Infrequent: </span>Breathing disorders. </p>
<p><span class="Italics">Musculoskeletal: Rare: </span><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Muscle pain</span>; <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle stiffness</span>, tightness and <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>; and bone and <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">skeletal pain</span>. </p>
<p><span class="Italics">Neurological: Infrequent: </span>Hypnagogic effects. <span class="Italics">Rare: </span>Memory effects, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, dreams, cognitive function disorders, disturbances of sense of taste, disorders of equilibrium, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, sedation, and <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>. </p>
<p><span class="Italics">Non-Site Specific: Infrequent: </span><span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, temperature regulation disturbances. <span class="Italics">Rare: </span><span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">Burning sensations</span>, hot and <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> sensations, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> sensations, and <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span>. </p>
<p><span class="Italics">Psychiatry: Infrequent: </span><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span>. <span class="Italics">Rare: </span>Depressive moods. </p>
<p><span class="Italics">Reproduction: Rare: </span>Sexual function disorders, female reproductive tract <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, reproductive <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, and fungal reproductive <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. </p>
<p><span class="Italics">Skin: Infrequent: </span><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>. <span class="Italics">Rare: </span><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Hair loss</span> and <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>; <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> and <span class="product-label-link" type="condition" conceptid="4029295" conceptname="Folliculitis">folliculitis</span>; disorders of sweat and sebum; <span class="product-label-link" type="condition" conceptid="4070025" conceptname="Cutaneous hypersensitivity">allergic skin reaction</span>; <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>; <span class="product-label-link" type="condition" conceptid="201093" conceptname="Infection of skin AND/OR subcutaneous tissue">skin infections</span>; <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span> and <span class="product-label-link" type="condition" conceptid="4317258" conceptname="Disorder of skin">dermatosis</span>; and <span class="product-label-link" type="condition" conceptid="4211923" conceptname="Nail changes">nail disorders</span>. </p>
<p><span class="Italics">Urology: Infrequent: </span><span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">Urinary frequency</span>. <span class="Italics">Rare: </span><span class="product-label-link" type="condition" conceptid="4128384" conceptname="Non-infective cystitis">Bladder inflammation</span>; <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span> and <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>; and urinary tract <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7ab1c360-e8a0-4fc0-bbaf-fe7549634e03"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience  </h2>
<p class="First">In addition to events reported in clinical trials, the following events have been identified during use of alosetron hydrochloride tablets in clinical practice. Because they were reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to alosetron hydrochloride tablets. </p>
<p><span class="Underline">Gastrointestinal:</span> Impaction, perforation, ulceration, small bowel <span class="product-label-link" type="condition" conceptid="192673" conceptname="Vascular insufficiency of intestine">mesenteric ischemia</span>. </p>
<p><span class="Underline">Neurological:</span> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>. </p>
<p><span class="Underline">Skin:</span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_0cef209a-da3e-430d-b9cf-e13037e577a5"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First"><span class="Italics">In vivo </span>data suggest that alosetron is primarily metabolized by cytochrome P450 (CYP) 1A2, with minor contributions from CYP3A4 and CYP2C9. Therefore, inducers or inhibitors of these enzymes may change the clearance of alosetron. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7560d8ed-0c53-45ac-98e4-78e486007559"></a><a name="section-7.1"></a><p></p>
<h2>7.1 CYP1A2 Inhibitors  </h2>
<p class="First">Fluvoxamine is a known strong inhibitor of CYP1A2 and also inhibits CYP3A4, CYP2C9, and CYP2C19. In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 to 200 mg/day for 16 days, with coadministration of alosetron 1 mg on the last day. Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold. Concomitant administration of alosetron and fluvoxamine is contraindicated <span class="Italics"><span class="Underline"><a href="#i4i_contraindications_id_4712fa45-2dfa-4135-a5bf-821afe504712">[see Contraindications (4.3)]</a></span></span>. </p>
<p>Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b053ce95-e5f1-4720-a9d8-ee938e2a081f"></a><a name="section-7.2"></a><p></p>
<h2>7.2 CYP3A4 Inhibitors  </h2>
<p class="First">Ketoconazole is a known strong inhibitor of CYP3A4. In a pharmacokinetic study, 38 healthy female subjects received ketoconazole 200 mg twice daily for 7 days, with coadministration of alosetron 1 mg on the last day. Ketoconazole increased mean alosetron plasma concentrations (AUC) by 29%. Caution should be used when alosetron and ketoconazole are administered concomitantly. Coadministration of alosetron and strong CYP3A4 inhibitors such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions. The effect of induction or inhibition of other pathways on exposure to alosetron and its metabolites is not known.  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5f808acf-f31b-4ed2-a9e5-4cd07e2ac9c0"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Other CYP Enzymes  </h2>
<p class="First"><span class="Italics">In vitro </span>human liver microsome studies and an <span class="Italics">in vivo </span>metabolic probe study demonstrated that alosetron did not inhibit CYP enzymes 3A4, 2C9, or 2C19. <span class="Italics">In vitro </span>at total drug concentrations 27-fold higher than peak plasma concentrations observed with the 1 mg dose, alosetron inhibited CYP enzymes 1A2 (60%) and 2E1 (50%). In an <span class="Italics">in vivo </span>metabolic probe study, alosetron did not inhibit CYP2E1 but did produce 30% inhibition of both CYP1A2 and N-acetyltransferase. Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine. The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). A clinical interaction study was also conducted with alosetron and the CYP3A4 substrate cisapride. No significant effects on cisapride metabolism or QT interval were noted. The effects of alosetron on monoamine oxidases and on intestinal first pass secondary to high intraluminal concentrations have not been examined. Based on the above data from <span class="Italics">in vitro </span>and <span class="Italics">in vivo </span>studies, it is unlikely that alosetron will inhibit the hepatic metabolic clearance of drugs metabolized by the CYP enzymes 2C9, 2C19, or 2E1. </p>
<p>Alosetron does not appear to induce the major cytochrome P450 drug-metabolizing enzyme 3A. Alosetron also does not appear to induce CYP enzymes 2E1 or 2C19. It is not known whether alosetron might induce other enzymes. </p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_8bf670bc-dc9d-446f-bb7b-62c3ad665e7b"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_c88fc2e0-63d8-4195-9839-9d253139c258"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Italics">Teratogenic Effects</span>: Pregnancy Category B. Reproduction studies have been performed in rats at doses up to 40 mg/kg/day (about 160 times the recommended human dose based on body surface area) and rabbits at oral doses up to 30 mg/kg/day (about 240 times the recommended daily human dose based on body surface area). These studies have revealed no evidence of impaired fertility or harm to the fetus due to alosetron. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, alosetron hydrochloride tablets should be used during pregnancy only if clearly needed. </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_1504ef92-8893-402e-92d7-e3a06c94c53b"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Alosetron and/or metabolites of alosetron are excreted in the breast milk of lactating rats. It is not known whether alosetron is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when alosetron hydrochloride tablets are administered to a nursing woman. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_31a43902-f897-42a6-ae0c-621043b5d6e1"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established. Use of alosetron hydrochloride tablets is not recommended in the pediatric population, based upon the risk of serious complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> and <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span> in adults. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_6a0abea0-1fb7-4ce5-b643-a765bae88e29"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">In some studies in healthy men or women, plasma concentrations were elevated by approximately 40% in individuals 65 years and older compared to young adults <span class="Italics"><span class="Underline"><a href="#i4i_warnings_precautions_id_996a356d-2a00-4884-8e4e-2a033317576b">[see Warnings and Precautions (5.1)]</a></span></span>. However, this effect was not consistently observed in men. </p>
<p>Postmarketing experience suggests that elderly patients may be at greater risk for complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> therefore, appropriate caution and follow-up should be exercised if alosetron hydrochloride tablets is prescribed for these patients <span class="Italics"><span class="Underline"><a href="#i4i_warnings_precautions_id_996a356d-2a00-4884-8e4e-2a033317576b">[see Warnings and Precautions (5.1)]</a></span></span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4ca0751b-9c63-4691-8b94-690814569a62"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Due to the extensive hepatic metabolism of alosetron, increased exposure to alosetron and/or its metabolites is likely to occur in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Alosetron should not be used in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and should be used with caution in patients with mild or moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. </p>
<p>A single 1 mg oral dose of alosetron was administered to 1 female and 5 male patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh score of 7 to 9) and to 1 female and 2 male patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh score of &gt;9). In comparison with historical data from healthy subjects, patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> displayed higher systemic exposure to alosetron. The female with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> displayed approximately 14-fold higher exposure, while the female with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> displayed approximately 1.6-fold higher exposure, than healthy females. Due to the small number of subjects and high intersubject variability in the pharmacokinetic findings, no definitive quantitative conclusions can be made. However, due to the greater exposure to alosetron in the female with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, alosetron should not be used in females with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics"><span class="Underline"><a href="#i4i_dosage_admin_id_b7d9679f-72a2-4695-a729-46cd045c164f">[see Dosage and Administration (2.2)</a></span></span><span class="Italics">, </span><span class="Italics"><span class="Underline"><a href="#i4i_contraindications_id_4712fa45-2dfa-4135-a5bf-821afe504712">Contraindications (4)]</a></span></span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ee4d821f-c9d8-4e01-a562-a44db20baecd"></a><a name="section-8.6"></a><p></p>
<h2>8.7 Renal Impairment   </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span> (creatinine clearance 4 to 56 mL/min) has no effect on the renal elimination of alosetron due to the minor contribution of this pathway to elimination. The effect of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on metabolite pharmacokinetics and the effect of end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> have not been assessed. </p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_05e02bde-6fb1-44bd-9bea-c7de4fddbd01"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">There is no specific antidote for <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of alosetron hydrochloride tablets. Patients should be managed with appropriate supportive therapy. Individual oral doses as large as 16 mg have been administered in clinical studies without significant adverse reactions. This dose is 8 times higher than the recommended total daily dose. Inhibition of the metabolic elimination and reduced first pass of other drugs might occur with <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> of alosetron hydrochloride tablets <span class="Italics"><span class="Underline"><a href="#i4i_interactions_id_0cef209a-da3e-430d-b9cf-e13037e577a5">[see Drug interactions (7)]</a></span></span>. </p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_7bb7e0bf-588a-440e-b1eb-1d06706bae93"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">The active ingredient in Alosetron Hydrochloride Tablets is alosetron hydrochloride (HCl), a potent and selective antagonist of the serotonin 5-HT<span class="Sub">3</span> receptor type. Chemically, alosetron is designated as 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H-pyrido[4,3-b]indol-1-one, monohydrochloride. Alosetron is achiral and has the empirical formula C<span class="Sub">17</span>H<span class="Sub">18</span>N<span class="Sub">4</span>O•HCl, representing a molecular weight of 330.8. Alosetron is a white to beige solid that has a solubility of 61 mg/mL in water, 42 mg/mL in 0.1M hydrochloric acid, 0.3 mg/mL in pH 6 phosphate buffer, and &lt;0.1 mg/mL in pH 8 phosphate buffer. The chemical structure of alosetron is: </p>
<div class="Figure">
<a name="id938"></a><img alt="chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e91c4a69-2ad5-4e21-a279-9e1302b1a3d3&amp;name=0c860716-4dd6-4c3a-95b6-23dc6605199d-01.jpg">
</div>
<p>Alosetron Hydrochloride Tablets are supplied for oral administration as 0.5 mg (white to off-white) and 1 mg (white to off-white) tablets. The 0.5 mg tablet contains 0.562 mg alosetron HCl equivalent to 0.5 mg alosetron, and the 1 mg tablet contains 1.124 mg alosetron HCl equivalent to 1 mg of alosetron. Each tablet also contains the inactive ingredients lactose (anhydrous), magnesium stearate, microcrystalline cellulose, and pregelatinized starch. </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_7bdbd3a8-7734-4ec8-88cf-ab065d0e7343"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_d9d56e57-2fa7-473c-a5b4-9ac6676b7afc"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Alosetron is a potent and selective 5-HT<span class="Sub">3</span> receptor antagonist. 5-HT<span class="Sub">3</span> receptors are ligand-gated cation channels that are extensively distributed on enteric neurons in the human gastrointestinal tract, as well as other peripheral and central locations. Activation of these channels and the resulting neuronal depolarization affect the regulation of <span class="product-label-link" type="condition" conceptid="4251315" conceptname="Visceral pain">visceral pain</span>, colonic transit, and gastrointestinal secretions, processes that relate to the pathophysiology of IBS. 5-HT<span class="Sub">3</span> receptor antagonists such as alosetron inhibit activation of non-selective cation channels, which results in the modulation of the enteric nervous system. </p>
<p>The cause of IBS is unknown. IBS is characterized by visceral <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> and <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span> of the gastrointestinal tract, which lead to abnormal sensations of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and motor activity. Following <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span> of the rectum, patients with IBS exhibit <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> at lower volumes than healthy volunteers. Following such <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>, alosetron reduced <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and exaggerated motor responses, possibly due to blockade of 5-HT<span class="Sub">3</span> receptors. </p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_9443ea44-3012-4712-95b4-60aeb417b181"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">In healthy volunteers and patients with IBS, alosetron (2 mg orally, twice daily for 8 days) increased colonic transit time without affecting orocecal transit time. In healthy volunteers, alosetron also increased basal jejunal water and sodium absorption after a single 4 mg dose. In patients with IBS, multiple oral dosages of alosetron (4 mg twice daily for 6.5 days) significantly increased colonic compliance. </p>
<p>Single oral doses of alosetron administered to healthy men produced a dose-dependent reduction in the flare response seen after intradermal injection of serotonin. Urinary 6-β-hydroxycortisol excretion decreased by 52% in elderly subjects after 27.5 days of alosetron 2 mg administered orally twice daily. This decrease was not statistically significant. In another study utilizing alosetron 1 mg administered orally twice daily for 4 days, there was a significant decrease in urinary 6-β-hydroxycortisol excretion. However, there was no change in the ratio of 6-β-hydroxycortisol to cortisol, indicating a possible decrease in cortisol production. The clinical significance of these findings is unknown. </p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_6122fd3b-5619-4b88-9d25-5b8931864a72"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The pharmacokinetics of alosetron have been studied after single oral doses ranging from 0.05 to 16 mg in healthy men. The pharmacokinetics of alosetron have also been evaluated in healthy women and men and in patients with IBS after repeated oral dosages ranging from 1 mg twice daily to 8 mg twice daily. </p>
<p><span class="Underline">Absorption: </span>Alosetron was rapidly absorbed after oral administration with a mean absolute bioavailability of approximately 50% to 60% (approximate range, 30% to &gt;90%). After administration of radiolabeled alosetron, only 1% of the dose was recovered in the feces as unchanged drug. Following oral administration of a 1 mg alosetron dose to young men, a peak plasma concentration of approximately 5 ng/mL occurred at 1 hour. In young women, the mean peak plasma concentration was approximately 9 ng/mL, with a similar time to peak. </p>
<p>Plasma concentrations were 30% to 50% lower and less variable in men compared to women given the same oral dose. Population pharmacokinetic analysis in IBS patients confirmed that alosetron concentrations were influenced by gender (27% lower in men). </p>
<p><span class="Underline">Food Effects: </span>Alosetron absorption is decreased by approximately 25% by co-administration with food, with a mean delay in time to peak concentration of 15 minutes <span class="Italics">[see Dosage and Administration (2.1)]</span>. </p>
<p><span class="Underline">Distribution: </span>Alosetron demonstrates a volume of distribution of approximately 65 to 95 L. Plasma protein binding is 82% over a concentration range of 20 to 4,000 ng/mL. </p>
<p><span class="Underline">Metabolism and Elimination: </span>Plasma concentrations of alosetron increase proportionately with increasing single oral doses up to 8 mg and more than proportionately at a single oral dose of 16 mg. Twice-daily oral dosing of alosetron does not result in accumulation. The terminal elimination half-life of alosetron is approximately 1.5 hours (plasma clearance is approximately 600 mL/min). Population pharmacokinetic analysis in patients with IBS confirmed that alosetron clearance is minimally influenced by doses up to 8 mg. </p>
<p>Renal elimination of unchanged alosetron accounts for only 13% of the dose. Renal clearance is approximately 112 mL/min. </p>
<p>A study with <span class="Sup">14</span>C-labeled alosetron in Caucasian males (n = 3) and females (n = 3) and an Asian male (n = 1) showed similar serum metabolite profiles. Unchanged alosetron was the major component in serum, with other metabolites being present at low concentrations, none amounting to more than 15% of the unmetabolized alosetron concentration. The circulating metabolites were identified as 6-hydroxy glucuronide, 6-hydroxy sulphate, 7-hydroxy sulphate, hydroxymethyl imidazole, and mono- and bis-oxygenated imidazole derivatives of alosetron. The metabolites are unlikely to contribute to the biological activity of alosetron. Of the circulating Phase I metabolites, only the hydroxymethyl imidazole has weak pharmacological activity, around 10-fold less potent than alosetron. Total recovery of radioactivity in the excreta was 85 ± 6%. The majority of the radiolabeled dose is excreted in the urine (74 ± 5%). The major urinary metabolites were the 6-hydroxy glucuronide and the mono- and bis-oxygenated imidazole derivatives of alosetron. 11 ± 4% of the radiolabeled dose was excreted in the feces with less than 1% of the dose being excreted as the unchanged alosetron. </p>
<p>Alosetron is metabolized by human microsomal cytochrome P450 (CYP), shown <span class="Italics">in vitro </span>to involve enzymes 2C9 (30%), 3A4 (18%), and 1A2 (10%). Non–CYP-mediated Phase I metabolic conversion also contributes to an extent of about 11%. However, <span class="Italics">in vivo </span>data suggest that CYP1A2 plays a more prominent role in alosetron metabolism (62 to 97% of alosetron clearance) based on correlation of alosetron clearance with <span class="Italics">in vivo </span>CYP1A2 activity measured by probe substrate, increased clearance induced by smoking, and inhibition of clearance by fluvoxamine <span class="Italics"><span class="Underline"><a href="#i4i_contraindications_id_4712fa45-2dfa-4135-a5bf-821afe504712">[see Contraindications (4)</a></span></span><span class="Italics">, </span><span class="Italics"><span class="Underline"><a href="#i4i_interactions_id_0cef209a-da3e-430d-b9cf-e13037e577a5">Drug Interactions (7)]</a></span></span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_e11be218-a203-489f-bd1e-0da6820ef1a1"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_73e770b3-6df6-4c89-8433-3da52d7d338f"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">In 2-year oral studies, alosetron was not carcinogenic in mice at doses up to 30 mg/kg/day or in rats at doses up to 40 mg/kg/day. These doses are about 60 to 160 times, respectively, the recommended human dose of alosetron of 2 mg/day (1 mg twice daily) based on body surface area. Alosetron was not genotoxic in the Ames tests, the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cell (L5178Y/TK<span class="Sup">±</span>) forward gene mutation test, the human lymphocyte chromosome aberration test, the ex vivo rat hepatocyte unscheduled DNA synthesis (UDS) test, or the <span class="Italics">in vivo </span>rat micronucleus test for mutagenicity. Alosetron at oral doses up to 40 mg/kg/day (about 160 times the recommended daily human dose based on body surface area) was found to have no effect on fertility and reproductive performance of male or female rats. </p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_12145a9e-f155-4a04-8bd8-6f92beb1706b"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_60f30825-c5b8-4320-8ead-1cf9be453096"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Dose-Ranging Study  </h2>
<p class="First">Data from a dose-ranging study of women (n = 85) who received alosetron hydrochloride tablets 0.5 mg twice daily indicated that the incidence of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (14%) was lower than that experienced by women receiving 1 mg twice daily (29%). Therefore, to lower the risk of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, alosetron hydrochloride tablets should be started at a dosage of 0.5 mg twice a day. The efficacy of the 0.5 mg twice-daily dosage in treating severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-predominant IBS has not been adequately evaluated in clinical trials <span class="Italics"><span class="Underline"><a href="#i4i_dosage_admin_id_b7d9679f-72a2-4695-a729-46cd045c164f">[see Dosage and Administration (2.1)]</a></span></span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4615473f-0943-4ca8-8fc1-1adcc8cc9e8d"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Efficacy Studies  </h2>
<p class="First">Alosetron hydrochloride has been studied in women with IBS in five 12-week US multicenter, randomized, double-blind, placebo-controlled clinical studies.</p>
<a name="_Refid_e9f1a11f-6969-4a72-8f97-34d31f947"></a><table width="100%">
<caption><span>Table 3: Efficacy Studies Conducted in Women With <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">Irritable Bowel Syndrome</span> (IBS) </span></caption>
<col width="11%">
<col width="55%">
<col width="13%">
<col width="21%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Study </p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">Patient Population </p></td>
<td class="Botrule Rrule Toprule" align="center">
<p class="First">Placebo </p>
<p>(n) </p>
</td>
<td class="Botrule Rrule Toprule" align="center">
<p class="First">Alosetron </p>
<p>Dose </p>
<p>(n) </p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">1 and 2 </p></td>
<td class="Botrule Rrule"><p class="First">Non-constipated women with IBS </p></td>
<td class="Botrule Rrule" align="center"><p class="First">(640) </p></td>
<td class="Botrule Rrule" align="center">
<p class="First">1 mg twice daily </p>
<p>(633) </p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">3 and 4 </p></td>
<td class="Botrule Rrule"><p class="First">Women with severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-predominant IBS (defined as bowel urgency ≥50% of days) </p></td>
<td class="Botrule Rrule" align="center"><p class="First">(515) </p></td>
<td class="Botrule Rrule" align="center">
<p class="First">1 mg twice daily </p>
<p>(778) </p>
</td>
</tr>
<tr>
<td class="Lrule Rrule" rowspan="3"><p class="First">5 </p></td>
<td class="Botrule Rrule" rowspan="3"><p class="First">Women with severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-predominant IBS (defined as average <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> ≥moderate, urgency ≥50% of days, and/or restriction of daily activities ≥25% of days) </p></td>
<td class="Botrule Rrule" align="center" rowspan="3"><p class="First">(176) </p></td>
<td class="Botrule Rrule" align="center">
<p class="First">0.5 mg once daily </p>
<p>(177) </p>
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center">
<p class="First">1 mg once daily </p>
<p>(175) </p>
</td></tr>
<tr class="Last"><td class="Botrule Lrule Rrule" align="center">
<p class="First">1 mg twice daily </p>
<p>(177) </p>
</td></tr>
</tbody>
</table>
<p><span class="Underline">Studies in Non-Constipated Women with <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">Irritable Bowel Syndrome</span></span>: Studies 1 and 2 were conducted in non-constipated women with IBS meeting the Rome Criteria<span class="Sup">1</span> for at least 6 months. Women with severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or a history of severe <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> were excluded. A 2-week run-in period established baseline IBS symptoms. </p>
<p>About two thirds of the women had <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-predominant IBS. Compared with placebo, 10% to 19% more women with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-predominant IBS who received alosetron hydrochloride tablets had adequate relief of IBS <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> and <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> during each month of the study. </p>
<p><span class="Underline">Studies in Women With Severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>-Predominant <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">Irritable Bowel Syndrome</span></span><span class="Bold">: </span>Alosetron hydrochloride tablets is indicated only for women with severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-predominant IBS <span class="Italics"><a href="#i4i_indications_id_95bdf1f4-a93f-44fa-ac01-03a319cf603f">[see Indications and Usage (1)]</a></span>. The efficacy of alosetron hydrochloride tablets in this subset of the women studied in clinical trials is supported by prospective and retrospective analyses. </p>
<p><span class="Italics">Prospective Analyses: </span>Studies 3 and 4 were conducted in women with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-predominant IBS and bowel urgency on at least 50% of days at entry. Women receiving alosetron hydrochloride tablets had significant increases over placebo (13% to 16%) in the median percentage of days with urgency control. </p>
<p>The lower gastrointestinal functions of stool consistency, stool frequency, and sense of incomplete evacuation were also evaluated by patients’ daily reports. Stool consistency was evaluated on a scale of 1 to 5 (1 = very hard, 2 = hard, 3 = formed, 4 = loose, and 5 = watery). At baseline, average stool consistency was approximately 4 (loose) for both treatment groups. During the 12 weeks of treatment, the average stool consistency decreased to approximately 3.0 (formed) for patients who received alosetron hydrochloride tablets and 3.5 for the patients who received placebo in the 2 studies. </p>
<p>At baseline, average stool frequency was approximately 3.2 per day for both treatment groups. During the 12 weeks of treatment, the average daily stool frequency decreased to approximately 2.1 and 2.2 for patients receiving alosetron hydrochloride tablets and 2.7 and 2.8 for patients receiving placebo in the 2 studies. </p>
<p>There was no consistent effect upon the sense of incomplete evacuation during the 12 weeks of treatment for patients receiving alosetron hydrochloride tablets as compared to patients receiving placebo in either study. </p>
<p>Study 5 was conducted in women with severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-predominant IBS and 1 or more of the following: frequent and severe <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, frequent bowel urgency or <span class="product-label-link" type="condition" conceptid="197675" conceptname="Incontinence of feces">fecal incontinence</span>, <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> or restriction of daily activities due to IBS. To evaluate the proportion of patients who responded to treatment, patients were asked every 4 weeks to compare their IBS symptoms during the previous month of treatment with how they usually felt during the 3 months prior to the study using an ordered 7-point scale (substantially worse to substantially improved). A responder was defined as a subject who reported moderate or substantial improvement on this global improvement scale (GIS). At Week 12, all three groups receiving alosetron hydrochloride tablets had significantly greater percentages of GIS responders compared to the placebo group (43% to 51% vs. 31%) using a Last Observation Carried Forward (LOCF) analysis. It should be noted that approximately 4% of subjects in each alosetron hydrochloride tablets dose group who were classified as responders using this approach were observed only through week 4. At each of the 4 week intervals of the treatment phase, all three dosages of alosetron hydrochloride tablets provided improvement in the average adequate relief rate of IBS <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, stool consistency, stool frequency, and sense of urgency compared with placebo. </p>
<p><span class="Italics">Retrospective Analyses: </span>In analyses of patients from Studies 1 and 2 who had <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-predominant IBS and indicated their baseline run-in IBS symptoms were severe at the start of the trial, alosetron hydrochloride tablets provided greater adequate relief of IBS <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> than placebo. In further analyses of Studies 1 and 2, 57% of patients had urgency at baseline on 5 or more days per week. In this subset, 32% of patients on alosetron hydrochloride tablets had urgency no more than 1 day in the last week of the trial, compared with 19% of patients on placebo. </p>
<p>In Studies 3 and 4, 66% of patients had urgency at baseline on 5 or more days per week. In this subset, 50% of patients on alosetron hydrochloride tablets had urgency no more than 1 day in the last week of the trial, compared with 29% of patients on placebo. Moreover, in the same subset, 12% on alosetron hydrochloride tablets had urgency no more than 2 days per week in any of the 12 weeks on treatment compared with 1% of placebo patients. </p>
<p><span class="Bold">Figure 1: Percent of Patients With Urgency on &gt;5 Days/Week at Baseline Who Improved to No More Than 1 Day in the Final Week</span></p>
<div class="Figure">
<a name="id1096"></a><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e91c4a69-2ad5-4e21-a279-9e1302b1a3d3&amp;name=0c860716-4dd6-4c3a-95b6-23dc6605199d-02.jpg">
</div>
<p>In Studies 1 and 2, patient-reported subjective outcomes related to IBS were assessed by questionnaires obtained at baseline and week 12. Patients in the more severe subset who received alosetron hydrochloride tablets reported less <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">difficulty sleeping</span>, less <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, fewer eating problems, and less interference with social activities and work/main activities due to IBS symptoms or problems compared to those who received placebo. Change in the impact of IBS symptoms and problems on emotional and mental distress and on physical and sexual activity in women who received alosetron hydrochloride tablets were not statistically different from those reported by women who received placebo. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b00008fa-0b6c-402f-9770-d8096943c4db"></a><a name="section-13.3"></a><p></p>
<h2>14.3 Long-Term Use  </h2>
<p class="First">In a 48-week multinational, double-blind, placebo-controlled study, alosetron hydrochloride tablets 1 mg twice daily was evaluated in 714 women with non-constipated IBS. A retrospective analysis of the subset of women with severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-predominant IBS (urgency on at least 10 days during the 2-week baseline period) was performed. Of the 417 patients with severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-predominant IBS, 62% completed the trial. </p>
<p>Alosetron hydrochloride tablets (n = 198) provided a greater average rate of adequate relief of IBS <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> (52% vs. 41%) and a greater average rate of satisfactory control of bowel urgency (60% vs. 48%) compared with placebo (n = 219). Significant improvement of these symptoms occurred for most of the 48-week treatment period with no evidence of <span class="product-label-link" type="condition" conceptid="4052861" conceptname="Tachyphylaxis">tachyphylaxis</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_6277f6d2-6dc3-4346-a455-ad4fa7bcdf8d"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<p class="First">1. Thompson WG, Creed F, Drossman DA, et al. Functional bowel disease and functional <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>. <span class="Italics">Gastroenterol Int</span>. 1992;5:75-91. </p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_732684e6-bb82-4e37-b092-1eace78d396a"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Alosetron Hydrochloride Tablets, 0.5 mg (0.562 mg alosetron HCl equivalent to 0.5 mg alosetron), are white to off-white, round biconvex tablets, debossed with 54 628 on one side and plain on the other side. </p>
<p>Bottles of 30 (NDC 0054-0295-13) with child-resistant closures. </p>
<p>Alosetron Hydrochloride Tablets, 1 mg (1.124 mg alosetron HCl equivalent to 1 mg alosetron), are white to off-white, round biconvex tablets, debossed with 54 974 on one side and plain on the other side. </p>
<p>Bottles of 30 (NDC 0054-0296-13) with child-resistant closures.</p>
<p><span class="Bold">Store at 20</span>° <span class="Bold">to</span><span class="Bold">25</span>°<span class="Bold">C (68</span>° <span class="Bold">to</span><span class="Bold">77</span>°<span class="Bold">F). [See USP Controlled Room Temperature.] Protect from light and moisture. </span></p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_b6032ac2-f750-4e1a-a60c-176aef7bde8a"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics">See Medication Guide.</span></p>
<p><span class="Bold">Prescriber and Patient Responsibilities</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Patients should be fully counseled on and understand the risks and benefits of alosetron hydrochloride tablets before an initial prescription is written. The patient may be educated by the enrolled prescriber or a healthcare provider under a prescriber’s direction. </span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Underline">Prescribers must: </span></span></p>
<dl>
<dt>•</dt>
<dd><span class="XmChange">counsel patients for whom alosetron hydrochloride tablets are appropriate about the benefits and risks of alosetron hydrochloride tablets and discuss the impact of IBS symptoms on the patient’s life. </span></dd>
<dt>•</dt>
<dd><span class="XmChange">give the patient a copy of the Medication Guide, which outlines the benefits and risks of alosetron hydrochloride tablets, and instruct the patient to read it carefully. Answer all questions the patient may have about alosetron hydrochloride tablets. The complete text of the Medication Guide is printed at the end of this document. </span></dd>
<dt>•</dt>
<dd><span class="XmChange">review the Patient Acknowledgement Form for alosetron hydrochloride tablets with the patient, answer all questions, and give a copy of the signed Patient Acknowledgement Form to the patient. </span></dd>
<dt>•</dt>
<dd><span class="XmChange">provide each patient with appropriate instructions for taking alosetron hydrochloride tablets. </span></dd>
</dl>
<p style="border-left:1px solid;"><span class="XmChange">Copies of the Patient Acknowledgement Form for alosetron hydrochloride tablets and additional copies of the Medication Guide are available by contacting the Alosetron REMS Program at 1-844-267-8675 or visiting www.AlosetronREMS.com. </span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Underline">Patients who are prescribed alosetron hydrochloride tablets should be instructed to: </span></span></p>
<dl>
<dt>•</dt>
<dd><span class="XmChange">read the Medication Guide before starting alosetron hydrochloride tablets and each time they refill their prescription. </span></dd>
<dt>•</dt>
<dd><span class="XmChange">not start taking alosetron hydrochloride tablets if they are constipated. </span></dd>
<dt>•</dt>
<dd><span class="XmChange">immediately discontinue alosetron hydrochloride tablets and contact their prescriber if they become constipated, or have symptoms of <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span> such as new or worsening <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span>, or blood in the stool. Contact their prescriber again if their <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> does not resolve after discontinuation of alosetron hydrochloride tablets. Resume alosetron hydrochloride tablets only if their <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> has resolved and after discussion with and the agreement of their treating prescriber. </span></dd>
<dt>•</dt>
<dd><span class="XmChange">stop taking alosetron hydrochloride tablets and contact their prescriber if alosetron hydrochloride tablets does not adequately control IBS symptoms after 4 weeks of taking 1 mg twice a day. </span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="ID_e5ff650d-1273-4d8a-9163-6f47848aa41f"></a><a name="section-17"></a><p></p>
<h1>Medication Guide</h1>
<p class="First"><span class="Bold">Alosetron (a-LOW-zeh-tron) Hydrochloride Tablets</span></p>
<table width="100%">
<col width="100%">
<tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule">
<p class="First"><span class="Bold">Before using alosetron hydrochloride tablets for the first time, you should: </span></p>
<dl>
<dt>•</dt>
<dd>Understand that alosetron hydrochloride tablets have serious risks for some people. </dd>
<dt>•</dt>
<dd>Read and follow the directions in this Medication Guide. </dd>
</dl>
<p>Sign a Patient Acknowledgement Form.</p>
</td></tr></tbody>
</table>
<p>Read this Medication Guide carefully before you sign the Patient Acknowledgement Form. You must sign the Patient Acknowledgement Form before you start alosetron hydrochloride tablets. Read the Medication Guide you get with each refill for alosetron hydrochloride tablets. There may be new information. This Medication Guide does not take the place of talking with your doctor. </p>
<p><span class="Bold">1. <span class="Underline">What is the most important information I should know about alosetron hydrochloride tablets? </span></span></p>
<p><span class="Bold">A. Alosetron hydrochloride tablets are a medicine only for some women with severe chronic <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">irritable bowel syndrome</span> (IBS) whose: </span></p>
<dl>
<dt>•</dt>
<dd>main problem is <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and </dd>
<dt>•</dt>
<dd>IBS symptoms have not been helped enough by other treatments. </dd>
</dl>
<p><span class="Bold">B. Some patients have developed serious bowel side effects while taking alosetron hydrochloride tablets. Serious bowel (intestine) side effects can happen suddenly, including the following. </span></p>
<p><span class="Bold">1. Serious complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>: </span>About 1 out of every 1,000 women who take alosetron hydrochloride tablets may get serious complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. These complications <span class="Bold">may lead to a hospital stay and, in rare cases, blood transfusions, surgery, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. </span>People who are older, who are weak from illness, or who take other constipating medicines may be more likely to have serious complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> with alosetron hydrochloride tablets. </p>
<p><span class="Bold">To lower your chances of getting serious complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, </span>do the following: </p>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">If you are constipated</span>, do not start taking alosetron hydrochloride tablets. </dd>
<dt>•</dt>
<dd>
<span class="Bold">If you get constipated while taking alosetron hydrochloride tablets</span>, stop taking it right away and call your doctor. </dd>
<dt>•</dt>
<dd>
<span class="Bold">If your <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> does not get better after stopping alosetron hydrochloride tablets</span>, call your doctor again. </dd>
<dt>•</dt>
<dd>
<span class="Bold">If you stopped taking alosetron hydrochloride tablets, do not start taking alosetron hydrochloride tablets again </span>unless your doctor tells you to do so. </dd>
</dl>
<p><span class="Bold">2. <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">Ischemic colitis</span> (reduced blood flow to the bowel): </span>About 3 out of every 1,000 women who take alosetron hydrochloride tablets over a 6-month period may get a serious problem where blood flow to parts of the large bowel is reduced. This is called <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>. The chance of getting <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span> when you take alosetron hydrochloride tablets for more than 6 months is not known. <span class="Bold"><span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">Ischemic colitis</span> may lead to a hospital stay and, in rare cases, blood transfusions, surgery, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></span>.</p>
<p><span class="Bold">To lower your chances of getting serious complications of <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>, stop taking alosetron hydrochloride tablets and call your doctor right away if you get: </span></p>
<dl>
<dt>•</dt>
<dd>new or worse <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in your stomach area (abdomen) or </dd>
<dt>•</dt>
<dd>blood in your bowel movements. </dd>
</dl>
<p><span class="Bold">C. Are alosetron hydrochloride tablets right for you? </span></p>
<p><span class="Bold">Alosetron hydrochloride tablets may be right for you if <span class="Underline">all</span> of these things are true about you: </span></p>
<dl>
<dt>•</dt>
<dd>Your doctor has told you that your symptoms are due to IBS. </dd>
<dt>•</dt>
<dd>Your IBS bowel problem is <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. </dd>
<dt>•</dt>
<dd>Your IBS has lasted for 6 months or longer. </dd>
<dt>•</dt>
<dd>You tried other IBS treatments and they did not give you the relief you need. </dd>
<dt>•</dt>
<dd>Your IBS is severe. </dd>
</dl>
<p>You can tell if your IBS is severe if <span class="Bold"><span class="Underline">at least 1 </span></span>of the following is true for you: </p>
<dl>
<dt>•</dt>
<dd>You have lots of painful <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> or <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span>. </dd>
<dt>•</dt>
<dd>You often cannot control the need to have a bowel movement, or you have “accidents? where your underwear gets dirty from <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> or bowel movements. </dd>
<dt>•</dt>
<dd>You cannot lead a normal home or work life because you need to be near a bathroom. </dd>
</dl>
<p>Enough testing has not been done to confirm alosetron hydrochloride tablets works in men or children under age 18. </p>
<p><span class="Bold">D. There is a special prescribing program for alosetron hydrochloride tablets. </span></p>
<p>Only doctors who have signed up with the Alosetron REMS Program should write prescriptions for alosetron hydrochloride tablets. As part of signing up, these doctors have said that they understand about IBS and the possible side effects of alosetron hydrochloride tablets. They have agreed to use a special sticker on <span class="Bold"><span class="Underline">written</span></span> prescriptions for alosetron hydrochloride tablets, so the pharmacist will know that the doctors have signed up with the Alosetron REMS Program. No telephone, facsimile, or computerized prescriptions are permitted with this program. Refills may be written on prescriptions.</p>
<p>You may be taught about alosetron hydrochloride tablets by your doctor or healthcare provider under a doctor’s direction. Your doctor will ask you to sign a Patient Acknowledgement Form after you read this Medication Guide for the first time. Signing the Patient Acknowledgement Form means that you understand the benefits and risks of alosetron hydrochloride tablets and that you have read and understand this Medication Guide. </p>
<p><span class="Bold">2. <span class="Underline">What are alosetron hydrochloride tablets? </span></span></p>
<p>Alosetron hydrochloride tablets are a medicine only for some women with severe chronic IBS whose: </p>
<dl>
<dt>•</dt>
<dd>main problem is <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and </dd>
<dt>•</dt>
<dd>IBS symptoms have not been helped enough by other treatments. </dd>
</dl>
<p>Alosetron hydrochloride tablets does not cure IBS, and it may not help every person who takes it. For those who are helped, alosetron hydrochloride tablets reduces lower stomach area (abdominal) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, the sudden need to have a bowel movement (bowel urgency), and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> from IBS. If you stop taking alosetron hydrochloride tablets, your IBS symptoms may return within 1 or 2 weeks to what they were before you started taking alosetron hydrochloride tablets. </p>
<p>Alosetron hydrochloride tablets are not recommended for children. </p>
<p><span class="Bold">3. <span class="Underline">Who should not take alosetron hydrochloride tablets? </span></span></p>
<p>Alosetron hydrochloride tablets are not right for everyone. <span class="Bold">Do not take alosetron hydrochloride tablets if <span class="Underline">any </span>of the following apply to you: </span></p>
<dl>
<dt>•</dt>
<dd>Your main IBS problem is <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> or you are constipated most of the time. </dd>
<dt>•</dt>
<dd>You have had a serious problem from <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. <span class="Bold">If you are constipated now, <span class="Underline">do not start taking alosetron hydrochloride tablets</span>. </span>
</dd>
<dt>•</dt>
<dd>You have had serious bowel blockages. </dd>
<dt>•</dt>
<dd>You have had blood flow problems to your bowels, such as <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>. </dd>
<dt>•</dt>
<dd>You have had blood clots. </dd>
<dt>•</dt>
<dd>You have had Crohn’s disease, <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, <span class="product-label-link" type="condition" conceptid="4109737" conceptname="Diverticulitis">diverticulitis</span>, or severe liver disease. </dd>
<dt>•</dt>
<dd>You do not understand this Medication Guide or the Patient Acknowledgement Form, or you are not willing to follow them. </dd>
<dt>•</dt>
<dd>You are taking fluvoxamine (LUVOX®). </dd>
</dl>
<p><span class="Bold">4. <span class="Underline">What should I talk about with my doctor before taking alosetron hydrochloride tablets? </span></span></p>
<p>Talk with your doctor: </p>
<dl>
<dt>•</dt>
<dd>about the possible benefits and risks of alosetron hydrochloride tablets. </dd>
<dt>•</dt>
<dd>about how much of a problem IBS is in your life and what treatments you have tried. </dd>
<dt>•</dt>
<dd>about any other illnesses you have and medicines you take or plan to take. These include prescription and non-prescription medicines, supplements, and herbal remedies. Certain illnesses and medicines can increase your chance of getting serious side effects while taking alosetron hydrochloride tablets. Other medicines may interact with how the body handles alosetron hydrochloride tablets. </dd>
<dt>•</dt>
<dd>about any allergies that you have. See the end of the Medication Guide for a complete list of ingredients in alosetron hydrochloride tablets. </dd>
<dt>•</dt>
<dd>if you are pregnant, planning to get pregnant, or breastfeeding. </dd>
</dl>
<p><span class="Bold">5. <span class="Underline">How should I take alosetron hydrochloride tablets</span></span><span class="Underline">? </span></p>
<dl>
<dt>•</dt>
<dd>Take alosetron hydrochloride tablets exactly as your doctor prescribes it. You can take alosetron hydrochloride tablets with or without food. </dd>
<dt>•</dt>
<dd>Begin with 0.5 mg two times a day for 4 weeks to see how alosetron hydrochloride tablets affects you. You and your doctor may decide that you should keep taking this dose if you are doing well. </dd>
<dt>•</dt>
<dd>Check with your doctor 4 weeks after starting alosetron hydrochloride tablets: <dl>
<dt>•</dt>
<dd>If you try 0.5 mg two times a day for 4 weeks, it may not control your symptoms. If you do not get <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> or other side effects from alosetron hydrochloride tablets, your doctor may increase your dose up to 1 mg two times a day.</dd>
<dt>•</dt>
<dd>If 1 mg two times a day does not work after 4 weeks, alosetron hydrochloride tablets is not likely to help you. You should stop taking it and call your doctor. </dd>
</dl>
</dd>
<dt>•</dt>
<dd>
<span class="Bold">If you miss a dose of alosetron hydrochloride tablets</span>, just skip that dose. Do <span class="Bold">not </span>take 2 doses the next time. Wait until the next time you are supposed to take it and then take your normal dose. </dd>
<dt>•</dt>
<dd>
<span class="Bold">Follow the important instructions in the section “What is the most important information I should know about alosetron hydrochloride tablets?? </span>about when you must stop taking the medicine and when you should call your doctor. </dd>
<dt>•</dt>
<dd>
<span class="Bold">If you see other doctors </span>about your IBS or side effects from alosetron hydrochloride tablets, tell the doctor who prescribed alosetron hydrochloride tablets. </dd>
</dl>
<p><span class="Bold">6. <span class="Underline">What are the possible side effects of alosetron hydrochloride tablets? </span></span></p>
<p><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> is the most common side effect among women with IBS who take alosetron hydrochloride tablets. <span class="Bold">Some patients have developed serious bowel side effects while taking alosetron hydrochloride tablets. </span>Read the section <span class="Bold">“What is the most important information I should know about alosetron hydrochloride tablets?? </span>at the beginning of this Medication Guide for information about the serious side effects you may get with alosetron hydrochloride tablets. </p>
<p>This Medication Guide does not tell you about all the possible side effects of alosetron hydrochloride tablets. Your doctor or pharmacist can give you a more complete list. </p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. </p>
<p><span class="Bold"><span class="Underline">7. How should I store alosetron hydrochloride tablets? </span></span></p>
<dl>
<dt>•</dt>
<dd>Store alosetron hydrochloride tablets at 68ºF to 77ºF (20ºC to 25ºC). [See USP Controlled Room Temperature.] </dd>
<dt>•</dt>
<dd>Protect alosetron hydrochloride tablets from light and getting wet (moisture). </dd>
</dl>
<p><span class="Bold">Keep alosetron hydrochloride tablets and all medicines out of the reach of children. </span></p>
<p><span class="Bold">8. <span class="Underline">General information about the safe and effective use of alosetron hydrochloride tablets </span></span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. If you have any questions or concerns about alosetron hydrochloride tablets, ask your doctor. Do not use alosetron hydrochloride tablets for a condition for which it was not prescribed. Do not share your medicine with other people. It may harm them.</p>
<p>Your doctor or pharmacist can give you more information about alosetron hydrochloride tablets that was written for healthcare professionals. You can also contact the Alosetron REMS Program (toll free) at 1-844-267-8675 or at <span class="Underline">www.AlosetronREMS.com</span>.</p>
<p><span class="Bold">9. <span class="Underline">What are the ingredients of alosetron hydrochloride tablets? </span></span></p>
<p><span class="Bold">Active Ingredient: </span>alosetron hydrochloride. </p>
<p><span class="Bold">Inactive Ingredients: </span>lactose (anhydrous), magnesium stearate, microcrystalline cellulose, and pregelatinized starch.</p>
<p><span class="Italics">This Medication Guide has been approved by the U.S. Food and Drug Administration. </span></p>
<p>Roxane Laboratories, Inc.</p>
<p>Columbus, Ohio 43216</p>
<p><span class="Bold">10006481/01 Revised February 2015</span></p>
<p>© RLI, 2015</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_cd2df83b-1e0c-4fde-b3ac-7d9e17e0af6a"></a><a name="section-18"></a><p></p>
<h1>Alosetron Hydrochloride Tablets, 0.5 mg / Bottle of 30 </h1>
<div class="Figure">
<a name="id778074728"></a><img alt="0054-0295-13" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e91c4a69-2ad5-4e21-a279-9e1302b1a3d3&amp;name=0054-0295-13.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_c67b75c3-fdda-4065-a8a5-4fcf41bb83ab"></a><a name="section-19"></a><p></p>
<h1>Alosetron Hydrochloride Tablets, 1 mg / Bottle of 30</h1>
<div class="Figure">
<a name="id-2035032334"></a><img alt="0054-0296-13" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e91c4a69-2ad5-4e21-a279-9e1302b1a3d3&amp;name=0054-0296-13-01.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ALOSETRON HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">alosetron hydrochloride tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0054-0295</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ALOSETRON HYDROCHLORIDE</strong> (ALOSETRON) </td>
<td class="formItem">ALOSETRON</td>
<td class="formItem">0.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">54;628</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0054-0295-13</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA200652</td>
<td class="formItem">07/15/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ALOSETRON HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">alosetron hydrochloride tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0054-0296</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ALOSETRON HYDROCHLORIDE</strong> (ALOSETRON) </td>
<td class="formItem">ALOSETRON</td>
<td class="formItem">1 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">54;974</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0054-0296-13</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0054-0296-25</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA200652</td>
<td class="formItem">07/15/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Roxane Laboratories, Inc.
							(833490464)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Roxane Laboratories, Inc. (833490464)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Boehringer Ingelheim Roxane Inc</td>
<td class="formItem"></td>
<td class="formItem">058839929</td>
<td class="formItem">MANUFACTURE(0054-0295, 0054-0296)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>e91c4a69-2ad5-4e21-a279-9e1302b1a3d3</div>
<div>Set id: e91c4a69-2ad5-4e21-a279-9e1302b1a3d3</div>
<div>Version: 1</div>
<div>Effective Time: 20150522</div>
</div>
</div> <div class="DistributorName">Roxane Laboratories, Inc.</div></p>
</body></html>
